共 50 条
Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine
被引:22
|作者:
Zamarin, Dmitriy
[1
]
Jazaeri, Amir A.
[2
]
机构:
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Gynecol Med Oncol Serv, New York, NY USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX USA
关键词:
Immunotherapy;
Ovarian cancer;
Cervical cancer;
Endometrial cancer;
Gynecologic cancers;
Checkpoint inhibitors;
Immuno-oncology;
PHASE-I TRIAL;
REGULATORY T-CELLS;
TUMOR-INFILTRATING LYMPHOCYTES;
FOLATE RECEPTOR-ALPHA;
CONDITIONALLY-REPLICATIVE ADENOVIRUS;
HUMAN-PAPILLOMAVIRUS TYPE-16;
EPITHELIAL OVARIAN-CANCER;
COLONY-STIMULATING FACTOR;
ANTIGEN-PRESENTING CELLS;
KINASE GENE-THERAPY;
D O I:
10.1016/j.ygyno.2015.12.030
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
During the past decade significant progress in the understanding of stimulatory and inhibitory signaling pathways in immune cells has reinvigorated the field of immuno-oncology. In this review we outline the current immunotherapy based approaches for the treatment of gynecological cancers, and focus on the emerging clinical data on immune checkpoint inhibitors, adoptive cell therapies, and vaccines. It is anticipated that in the coming years biomarker-guided clinical trials, will provide for a better understanding of the mechanisms of response and resistance to immunotherapy, and guide combination treatment strategies that will extend the benefit from immunotherapy to patients with gynecologic cancers. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:86 / 94
页数:9
相关论文